265 related articles for article (PubMed ID: 10944135)
1. Natural course of neuroblastoma detected by mass screening: s 5-year prospective study at a single institution.
Nishihira H; Toyoda Y; Tanaka Y; Ijiri R; Aida N; Takeuchi M; Ohnuma K; Kigasawa H; Kato K; Nishi T
J Clin Oncol; 2000 Aug; 18(16):3012-7. PubMed ID: 10944135
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract][Full Text] [Related]
3. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
4. Observation of untreated patients with neuroblastoma detected by mass screening: a "wait and see" pilot study.
Yoneda A; Oue T; Imura K; Inoue M; Yagi K; Kawa K; Nishikawa M; Morimoto S; Nakayama M
Med Pediatr Oncol; 2001 Jan; 36(1):160-2. PubMed ID: 11464874
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening.
Tanaka M; Kigasawa H; Kato K; Ijiri R; Nishihira H; Aida N; Ohama Y; Tanaka Y
Pediatr Blood Cancer; 2010 Apr; 54(4):573-8. PubMed ID: 20049932
[TBL] [Abstract][Full Text] [Related]
6. Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute.
Nishio N; Mimaya J; Nara T; Takashima Y; Horikoshi Y; Urushihara N; Hasegawa S; Aoki K; Hamasaki M
Pediatr Int; 2006 Dec; 48(6):531-5. PubMed ID: 17168969
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous regression of localized neuroblastoma detected by mass screening.
Yamamoto K; Hanada R; Kikuchi A; Ichikawa M; Aihara T; Oguma E; Moritani T; Shimanuki Y; Tanimura M; Hayashi Y
J Clin Oncol; 1998 Apr; 16(4):1265-9. PubMed ID: 9552024
[TBL] [Abstract][Full Text] [Related]
8. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study.
Oue T; Inoue M; Yoneda A; Kubota A; Okuyama H; Kawahara H; Nishikawa M; Nakayama M; Kawa K
J Pediatr Surg; 2005 Feb; 40(2):359-63. PubMed ID: 15750929
[TBL] [Abstract][Full Text] [Related]
9. Fluctuation in the concentrations of vanillylmandelic acid and homovanillic acid in mass screening for neuroblastoma.
Nishi M; Miyake H; Takeda T; Yamashiro K; Takasugi N; Hanai J; Kawai T
Eur J Pediatr; 1990 Sep; 149(12):859-61. PubMed ID: 2226572
[TBL] [Abstract][Full Text] [Related]
10. The relationship between homovanillic/vanillylmandelic acid ratios and prognosis in neuroblastoma.
Nishi M; Miyake H; Takeda T; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hirama T; Ishikawa Y; Kudoh T; Azuma H; Takase A
Oncol Rep; 1998; 5(3):631-3. PubMed ID: 9538165
[TBL] [Abstract][Full Text] [Related]
11. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma. Mass screening for early detection and its prognosis.
Sawada T; Kidowaki T; Sakamoto I; Hashida T; Matsumura T; Nakagawa M; Kusunoki T
Cancer; 1984 Jun; 53(12):2731-5. PubMed ID: 6722733
[TBL] [Abstract][Full Text] [Related]
13. Mass screening for neuroblastoma in Japan.
Sawada T; Sugimoto T; Kawakatsu H; Matsumura T; Matsuda Y
Pediatr Hematol Oncol; 1991; 8(2):93-109. PubMed ID: 1863547
[TBL] [Abstract][Full Text] [Related]
14. Mass screening for neuroblastoma in Miyagi Prefecture.
Itano M; Morita S; Fujie H; Ohashi Y; Minegishi N; Minegishi M; Yamaguchi Y; Sato T; Tsuchiya S; Konno T
Tohoku J Exp Med; 1992 Oct; 168(2):137-9. PubMed ID: 1306297
[TBL] [Abstract][Full Text] [Related]
15. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1986 Dec; 16(4):351-5. PubMed ID: 3795531
[TBL] [Abstract][Full Text] [Related]
16. Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan.
Suita S; Zaizen Y; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Ueda K; Tasaka H; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Yano H; Akiyama H; Ikeda K
J Pediatr Surg; 1996 Apr; 31(4):555-8. PubMed ID: 8801312
[TBL] [Abstract][Full Text] [Related]
17. Role of ultrasound in managing neuroblastoma detected by mass screening: a proposed ultrasonographic grading for children with neuroblastoma.
Hirata T; Tatara H; Zaizen Y; Suita S; Matsuzaki A; Ueda K
J Clin Ultrasound; 1995 Jun; 23(5):305-13. PubMed ID: 7642769
[TBL] [Abstract][Full Text] [Related]
18. Urinary dopamine/noradrenaline and dopamine/vanillylmandelic acid ratios as a reflection of different biology of adrenergic clones in children's neuroblastic tumors.
Izbicki T; Bozek J; Perek D; Wozniak W
J Pediatr Surg; 1991 Oct; 26(10):1230-4. PubMed ID: 1779334
[TBL] [Abstract][Full Text] [Related]
19. Past and future of neuroblastoma screening in Japan.
Sawada T
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
[TBL] [Abstract][Full Text] [Related]
20. Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Jpn J Clin Oncol; 1990 Sep; 20(3):268-70. PubMed ID: 2255102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]